Cardiology Research Department, East Sussex Hospitals NHS Trust, Eastbourne District General Hospital, Eastbourne, United Kingdom.
Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
Pacing Clin Electrophysiol. 2021 Jul;44(7):1176-1184. doi: 10.1111/pace.14282. Epub 2021 Jun 11.
There is limited data using continuous monitoring to assess outcomes of atrial fibrillation (AF) ablation. This study assessed long-term outcomes of AF ablation in patients with implantable cardiac devices.
207 patients (mean age 68.1 ± 9.5, 50.3% men) undergoing ablation for symptomatic AF were followed up for a mean period of 924.5 ± 636.7 days. Techniques included The Pulmonary Vein Ablation Catheter (PVAC) (59.4%), cryoablation (17.4%), point by point (14.0%) and The Novel Irrigated Multipolar Radiofrequency Ablation Catheter (nMARQ) (9.2%).
130 (62.8%) patients had paroxysmal AF (PAF) and 77 (37.2%) persistent AF. First ablation and repeat ablation reduced AF burden significantly (relative risk 0.91, [95% CI 0.89 to 0.94]; P <0.0001 and 0.90, [95% CI, 0.86-0.94]; P <0.0001). Median AF burden in PAF patients reduced from 1.05% (interquartile range [IQR], 0.1%-8.70%) to 0.10% ([IQR], 0%-2.28%) at one year and this was maintained out to four-years. Persistent AF burden reduced from 99.9% ([IQR], 51.53%-100%) to 0.30% ([IQR], 0%-77.25%) at one year increasing to 87.3% ([IQR], 4.25%-100%) after four years. If a second ablation was required, point-by-point ablation achieved greater reduction in AF burden (relative risk, 0.77 [95% CI, 0.65-0.91]; P <0.01).
Ablation reduces AF burden both acutely and in the long-term. If a second ablation was required the point-by-point technique achieved greater reductions in AF burden than "single-shot" technologies. Persistent AF burden increased to near pre ablation levels by year 4 suggesting a different mechanism from PAF patients where this increase did not occur.
使用连续监测评估心房颤动 (AF) 消融的结果的数据有限。本研究评估了植入式心脏设备患者 AF 消融的长期结果。
207 名(平均年龄 68.1 ± 9.5,50.3%为男性)因有症状的 AF 而接受消融治疗的患者接受了平均 924.5 ± 636.7 天的随访。消融技术包括肺静脉消融导管(PVAC)(59.4%)、冷冻消融(17.4%)、逐点消融(14.0%)和新型灌流多极射频消融导管(nMARQ)(9.2%)。
130 名(62.8%)患者为阵发性 AF(PAF),77 名(37.2%)为持续性 AF。首次消融和重复消融显著降低 AF 负荷(相对风险 0.91,[95%CI 0.89 至 0.94];P <0.0001 和 0.90,[95%CI,0.86-0.94];P <0.0001)。PAF 患者的中位 AF 负荷从 1.05%(四分位距 [IQR],0.1%至 8.70%)降至 1 年时的 0.10%(IQR,0%至 2.28%),且这一数值在 4 年内保持稳定。持续性 AF 负荷从 99.9%(IQR,51.53%至 100%)降至 1 年时的 0.30%(IQR,0%至 77.25%),并在 4 年后增加至 87.3%(IQR,4.25%至 100%)。如果需要第二次消融,逐点消融可实现更大程度的 AF 负荷降低(相对风险,0.77 [95%CI,0.65-0.91];P <0.01)。
消融可在急性和长期内降低 AF 负荷。如果需要第二次消融,逐点技术可实现比“单次射击”技术更大程度的 AF 负荷降低。持续性 AF 负荷在 4 年内增加至接近消融前水平,表明与 PAF 患者不同的机制,在后者中未发生这种增加。